Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. (Q52668506)

5 May 2018

title

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. (English)

1 reference

5 May 2018

E Costello

8

0 references

Bengt Glimelius

19

object named as

B Glimelius

1 reference

5 May 2018

26

M W Büchler

1 reference

5 May 2018

N O Elander

1

1 reference

5 May 2018

K Aughton

2

1 reference

5 May 2018

P Ghaneh

3

1 reference

5 May 2018

J P Neoptolemos

4

1 reference

5 May 2018

D H Palmer

5

1 reference

5 May 2018

T F Cox

6

1 reference

5 May 2018

F Campbell

7

1 reference

5 May 2018

C M Halloran

9

1 reference

5 May 2018

J R Mackey

10

1 reference

5 May 2018

A G Scarfe

11

1 reference

5 May 2018

J W Valle

12

1 reference

5 May 2018

A C McDonald

13

1 reference

5 May 2018

R Carter

14

1 reference

5 May 2018

N C Tebbutt

15

1 reference

5 May 2018

D Goldstein

16

1 reference

5 May 2018

J Shannon

17

1 reference

5 May 2018

C Dervenis

18

1 reference

5 May 2018

M Deakin

20

1 reference

5 May 2018

R M Charnley

21

1 reference

5 May 2018

Alan Anthoney

22

1 reference

5 May 2018

M M Lerch

23

1 reference

5 May 2018

J Mayerle

24

1 reference

5 May 2018

A Oláh

25

1 reference

5 May 2018

W Greenhalf

27

1 reference

5 May 2018

European Study Group for Pancreatic Cancer

28

1 reference

5 May 2018

language of work or name

English

0 references

publication date

8 March 2018

1 reference

5 May 2018

British Journal of Cancer

published in

1 reference

5 May 2018

volume

118

1 reference

5 May 2018

page(s)

947-954

1 reference

5 May 2018

issue

7

1 reference

5 May 2018

Creative Commons Attribution 4.0 International

copyright license

start time

8 March 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/s41416-018-0004-2

0 references

cites work

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

2 November 2018

Cancer statistics, 2016

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

New biomarkers and targets in pancreatic cancer and their application to treatment

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Use of archived specimens in evaluation of prognostic and predictive biomarkers

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

5-Fluorouracil: mechanisms of action and clinical strategies

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5931115

Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins

30 November 2018

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0004-2

7 January 2021

Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0004-2

7 January 2021

Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0004-2

7 January 2021

Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0004-2

7 January 2021

Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0004-2

7 January 2021

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0004-2

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0004-2

7 January 2021

Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0004-2

7 January 2021

10.1038/S41416-018-0004-2

Identifiers

DOI

1 reference

5 May 2018

0 references

1 reference

5 May 2018